논문명
Correlation of HER2, p95HER2 and HER3 expression and treatment outcome of lapatinib plus capecitabine in her2-positive metastatic breast cancer
발표지
PLoS One
발표년월
2012.07
공동연구자
Han SW, Cha Y, Paquet A, Huang W, Weidler J, Lie Y, Sherwood T, Bates M, Haddad M, Park IH, Oh DY, Lee KS, Im SA, Bang YJ, Ro J, Kim TY.
논문명
Methylation and microsatellite status and recurrence following adjuvant FOLFOX in colorectal cancer
발표지
Int J Cancer
발표년월
2013.05
공동연구자
Han SW, Lee HJ, Bae JM, Cho NY, Lee KH, Kim TY, Oh DY, Im SA, Bang YJ, Jeong SY, Park KJ, Park JG, Kang GH, Kim TY.
논문명
Prognostic implication of mucinous histology in colorectal cancer patients treated with adjuvant FOLFOX chemotherapy
발표지
Br J Cancer
발표년월
2013.05
공동연구자
Lee DW, Han SW, Lee HJ, Rhee YY, Bae JM, Cho NY, Lee KH, Kim TY, Oh DY, Im SA, Bang YJ, Jeong SY, Park KJ, Park JG, Kang GH, Kim TY.
논문명
Targeted sequencing of cancer-related genes in colorectal cancer using next-generation sequencing
발표지
PLoS One
발표년월
2013.05
공동연구자
Han SW, Kim HP, Shin JY, Jeong EG, Lee WC, Lee KH, Won JK, Kim TY, Oh DY, Im SA, Bang YJ, Jeong SY, Park KJ, Park JG, Kang GH, Seo JS, Kim JI, Kim TY.
논문명
RNA editing in RHOQ promotes invasion potential in colorectal cancer
발표지
J Exp Med
발표년월
2014.04
공동연구자
Han SW, Kim HP, Shin JY, Jeong EG, Lee WC, Kim KY, Park SY, Lee DW, Won JK, Jeong SY, Park KJ, Park JG, Kang GH, Seo JS, Kim JI, Kim TY.
논문명
KRAS mutation is associated with worse prognosis in stage III or high-risk stage II colon cancer patients treated with adjuvant FOLFOX
발표지
Ann Surg Oncol
발표년월
2015 Jan
공동연구자
Lee DW, Kim KJ, Han SW, Lee HJ, Rhee YY, Bae JM, Cho NY, Lee KH, Kim TY, Oh DY, Im SA, Bang YJ, Jeong SY, Park KJ, Park JG, Kang GH, Kim TY.
논문명
Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells.
발표지
Mol Cancer Ther
발표년월
2009 Sep
공동연구자
Yoon YK, Kim HP, Han SW, Hur HS, Oh do Y, Im SA, Bang YJ, Kim TY.
논문명
Epidermal growth factor receptor intron 1 CA dinucleotide repeat polymorphism and survival of advanced gastric cancer patients treated with cetuximab plus modified FOLFOX6.
발표지
Cancer Sci
발표년월
2009 Nov
공동연구자
Han SW, Oh DY, Im SA, Park SR, Lee KW, Song HS, Lee NS, Lee KH, Choi IS, Lee MH, Kim MA, Kim WH, Bang YJ, Kim TY
논문명
Lapatinib, a dual EGFR and HER2 tyrosine kinase inhibitor, downregulates thymidylate synthase by inhibiting the nuclear translocation of EGFR and HER2.
발표지
PLoS One
발표년월
2009 Jun
공동연구자
Kim HP, Yoon YK, Kim JW, Han SW, Hur HS, Park J, Lee JH, Oh DY, Im SA, Bang YJ, Kim TY.
논문명
Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer.
발표지
Br J Cancer
발표년월
2009 Jan
공동연구자
Han SW, Oh DY, Im SA, Park SR, Lee KW, Song HS, Lee NS, Lee KH, Choi IS, Lee MH, Kim MA, Kim WH, Bang YJ, Kim TY.
논문명
The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer.
발표지
BMC Cancer
발표년월
2008 Oct
공동연구자
Rhee J, Han SW, Oh DY, Kim JH, Im SA, Han W, Park IA, Noh DY, Bang YJ, Kim TY.
논문명
Modified FOLFOX-6 chemotherapy in advanced gastric cancer: Results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker.
발표지
BMC Cancer
발표년월
2008 May
공동연구자
Keam B, Im SA, Han SW, Ham HS, Kim MA, Oh DY, Lee SH, Kim JH, Kim DW, Kim TY, Heo DS, Kim WH, Bang YJ
논문명
"Combined lapatinib and cetuximab enhance cytotoxicity against gefitinib-resistant lung cancer cells.
발표지
Mol Cancer Ther
발표년월
2008 Mar
공동연구자
Kim HP, Han SW, Kim SH, Im SA, Oh DY, Bang YJ, Kim TY.
논문명
Mucoepidermoid carcinoma of lung: potential target of EGFR-directed treatment.
발표지
Lung Cancer
발표년월
2008 Jul
공동연구자
Han SW, Kim HP, Jeon YK, Oh DY, Lee SH, Kim DW, Im SA, Chung DH, Heo DS, Bang YJ, Kim TY.
논문명
"Chasing targets for EGFR tyrosine kinase inhibitors in non-small-cell lung cancer: Asian perspectives.
발표지
Expert Rev Mol Diagn
발표년월
2007 Nov
공동연구자
Kim TY, Han SW, Bang YJ.
논문명
Clinical predictors versus epidermal growth factor receptor mutation in gefitinib-treated non-small-cell lung cancer patients.
발표지
Lung Cancer
발표년월
2006 Nov
공동연구자
Han SW, Kim TY, Lee KH, Hwang PG, Jeon YK, Oh DY, Lee SH, Kim DW, Im SA, Chung DH, Heo DS, Bang YJ.
논문명
Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation.
발표지
Clin Cancer Res
발표년월
2006 Apr
공동연구자
Han SW, Kim TY, Jeon YK, Hwang PG, Im SA, Lee KH, Kim JH, Kim DW, Heo DS, Kim NK, Chung DH, Bang YJ.
논문명
Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib.
발표지
J Clin Oncol
발표년월
2005 Apr
공동연구자
Han SW, Kim TY, Hwang PG, Jeong S, Kim J, Choi IS, Oh DY, Kim JH, Kim DW, Chung DH, Im SA, Kim YT, Lee JS, Heo DS, Bang YJ, Kim NK.
논문명
"Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa, ZD1839) in chemotherapy-resistant non-small cell lung cancer.
발표지
Int J Cancer
발표년월
2005 Jan
공동연구자
Han SW, Hwang PG, Chung DH, Kim DW, Im SA, Kim YT, Kim TY, Heo DS, Bang YJ, Kim NK.
논문명
Intron 1 CA dinucleotide repeat polymorphism and mutations of epidermal growth factor receptor and gefitinib responsiveness in non-small-cell lung cancer.
발표지
Pharmacogenet Genomics
발표년월
2007 May
공동연구자
Han SW, Jeon YK, Lee KH, Keam B, Hwang PG, Oh DY, Lee SH, Kim DW, Im SA, Chung DH, Heo DS, Bang YJ, Kim TY.